News & Events Archives - Page 8 of 21

Exosomal circRNA-0008302 from Adipose-derived Stem Cells Protects Against Myocardial Injury

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at investigating the expression and therapeutic potential of circRNAs from adipose-derived stem cell (ADSC) exosomes (ADSC-Exos) for cardiomyocyte injury.

Differentially expressed circRNAs were screened between ADSCs (more…)

Reproducibility of a New Method to Assess Endothelial Function According to Peripheral Arterial Volume

Announcing a new article publication for Cardiovascular Innovations and Applications journal. The assessment of endothelial function is crucial for understanding cardiovascular disease progression. Reliable, convenient non-invasive methods are necessary for evaluating endothelial function. Peripheral arterial volume (PAV), measured at the fingertip, is a novel approach for which limited reproducibility data are available. (more…)

Four-Dimensional XStrain Echocardiographic Assessment of Left Ventricular Strain and Rotational Mechanics

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Because of its excellent ability to non-invasively assess left ventricular (LV) systolic function, two-dimensional speckle tracking echocardiography (STE) is increasingly being used in echocardiographic laboratories worldwide. Two-dimensional STE is the most sought-after method to evaluate LV strain, rotation, twist and torsion. (more…)

Transcatheter Aortic Valve Replacement in Patients ≥80 and <80 Years of Age with Aortic Valve Stenosis at Moderate Surgical Risk: Findings from an Observational Study in the Vietnamese Population

Announcing a new article publication for Cardiovascular Innovations and Applications journal. The increasing number of elderly patients with severe aortic valve stenosis undergoing transcatheter aortic valve replacement (TAVR) has prompted concerns regarding their clinical outcomes compared with the younger population. This study evaluated the outcomes of TAVR on the basis (more…)

Pregnancy History is Critical in Our Female Patients

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Cardiovascular disease remains the leading cause of death amongst women. Pregnancy reflects a time of significant cardiovascular stress during a woman’s life, with associated significant hemodynamic changes that can exacerbate underlying cardiovascular disease (CVD) or un-mask previously unknown CVD conditions. Women are now advancing in age prior to conception and entering childbearing years with a higher incidence of CVD conditions and risk factors. In turn, pregnancy complications and other reproductive conditions can pre-dispose to future cardiovascular risk. Thus, it is important to recognize pregnancy and reproductive history, as this can also serve as an important window into future cardiovascular disease risk.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2024.0014

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Ki Park. Pregnancy History is Critical in Our Female Patients. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2024.0014

A 24-Week, Multi-Center, Randomized, Open-Label Clinical Trial Comparing the Effects of Xuezhikang and Atorvastatin on Glucose Metabolism in Patients with Dyslipidemia and Prediabetes (XTREME Study): Design of the Study Protocol

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Statins, a first-line therapeutic option for atherosclerotic cardiovascular disease (ASCVD), have prompted concerns regarding dysglycemia and diabetes, thus posing a dilemma in treating patients with prediabetes. Xuezhikang (XZK) decreases blood cholesterol levels without affecting glucose metabolism, and may serve as a potential substitute.

The XTREME study is a prospective, randomized, open-label, multi-center trial evaluating whether XZK 1200 mg/d, compared with atorvastatin 20 mg/d, has favorable effects on HbA1c levels after 24 weeks of treatment in patients with dyslipidemia and prediabetes. After a 1-week run-in period for adherence assessment, the study will randomly assign (1:1) 392 patients meeting the protocol inclusion criteria to one of two treatment groups: an experimental group (XZK 1200 mg/day) or a control group (atorvastatin 20 mg/day). All participants will be recruited from approximately 20 Chinese medical centers. The primary endpoint will be change in HbA1c level from baseline to 24 weeks, or before anti-diabetic therapy initiation within 24 weeks. The key secondary outcomes will include other biomarkers reflecting blood glucose or lipid metabolism.

Delaying diabetes is desirable for individuals with prediabetes. The XTREME trial presents a unique opportunity to demonstrate whether XZK might provide an alternative to statins for patients with dyslipidemia and prediabetes.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2024.0010

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Lan Fu, Yiqun Zhang and Xin Du et al. A 24-Week, Multi-Center, Randomized, Open-Label Clinical Trial Comparing the Effects of Xuezhikang and Atorvastatin on Glucose Metabolism in Patients with Dyslipidemia and Prediabetes (XTREME Study): Design of the Study Protocol. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2024.0010

Identification of Potential Targets of Stress Cardiomyopathy by a Machine Learning Algorithm

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Stress cardiomyopathy (SCM) is a reversible, self-limiting condition that manifests as left ventricular insufficiency. The incidence of stress cardiomyopathy has increased because of increasing mental and social stress, but the exact pathophysiological mechanisms remain unclear.

To elucidate the critical molecules in the pathogenesis of SCM and the functional changes that they mediate, data for a healthy control group and stress cardiomyopathy (SCM) group was downloaded from the Gene Expression Omnibus database, differential analysis was performed, and the results of GO and KEGG enrichment analysis was analysed to describe SCM-associated genes and functions. Lasso, random forest, SVM-RFM, and Friends analysis were used to screen hub genes; CIBERSORT and MCPcounter were used to explore the relationship between SCM and immunity; and an animal model of SCM was constructed to conduct bidirectional verification of the obtained results.

In total, 21 samples (6 healthy, 15 SCM) were used in this study. Overall, 39 DEGs (absolute fold change ≥ 1; P < 0.05), including 23 upregulated and 16 downregulated genes in SCM, were extracted. Three common hub genes (PLAT, SEMA6B, and CRP) were finally screened. It was further confirmed that functional changes in SCM were concentrated in immunity and coagulation functions.

Three key genes (PLAT, SEMA6B, and CRP) in SCM were identified by machine learning, and the major functional changes leading to SCM, and relationships of SCM with immunity, were identified.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2024.0011

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Xuexin Jin, Xuanrui Ji and Hongpeng Yin et al. Identification of Potential Targets of Stress Cardiomyopathy by a Machine Learning Algorithm. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2024.0011

Cardiovascular Innovations and Applications now indexed by SCOPUS

We are happy to announce this very good news to all authors, editors, reviewers and readers. scopus

Cardiovascular Innovations and Applications will be indexed by SCOPUS from February 26^th, 2024. The bibliographic database managed by Elsevier covers high-ranking peer-reviewed journals in the technical, medical and social sciences.

On this occasion, congratulations to Professor Jamie B. Conti and Professor Jianzeng Dong, Cardiovascular Innovations and Applications editorial team and all contributors, reviewers, readers and editorial assistants for making it happen.

This news means that even more researchers and scientists will get access to high-quality research papers published in Cardiovascular Innovations and Applications.

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

IL-6 and D-dimer Levels at Admission Predict Cardiac Injury and Early Mortality during SARS-CoV-2 Infection

Announcing a new article publication for Cardiovascular Innovations and Applications journal. The activation of immune and thrombotic biomarkers at admission, and their ability to predict cardiac injury and mortality patterns in COVID-19, remains unclear.

This retrospective cohort study included 170 patients with COVID-19 with cardiac injury at the time of admission to Tongji Hospital in Wuhan between January 29, 2020, and March 8, 2020. The temporal evolution of inflammatory cytokines, coagulation markers, clinical treatment, and mortality were analyzed. Continuous variables are expressed as median (interquartile range).

(more…)

Protocol for a Single-Center Randomized Controlled Trial of Percutaneous Coronary Intervention Via Distal Transradial Access Versus Transradial Access

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Although transradial access (TRA) has become the main vascular access for coronary intervention, its high radial artery occlusion rate limits its application in some patients. Studies have shown that compared with TRA, distal transradial access (dTRA) with the snuffbox area or the Hegu acupoint area as the puncture point significantly decreases the incidence of radial artery occlusion. However, no randomized controlled study has confirmed the safety and efficacy of coronary artery intervention via dTRA in China.

This single-center, prospective, randomized controlled, superiority open-label study will enroll 428 consecutive patients with coronary heart disease undergoing percutaneous coronary intervention as the study population. After preoperative evaluation, the participants will be randomly divided into a study group (dTRA) and control group (TRA) in a 1:1 ratio. The primary endpoint (radial artery occlusion at 24 hours after operation) and secondary endpoint events will be evaluated and recorded.

This study has been registered in the Chinese Clinical Trial Registry (registration number: ChiCTR2300073902).

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2024.0015

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Minghao Liu, Huanhuan Wang and Lijian Gao et al. Protocol for a Single-Center Randomized Controlled Trial of Percutaneous Coronary Intervention Via Distal Transradial Access Versus Transradial Access. CVIA. 2024. Vol. 9(1). DOI: 10.15212/CVIA.2024.0015

CVIA Journal

Category: News & Events